Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial

Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial

Background The Camrelizumab Plus Apatinib in Patients with Advanced Cervical Cancer trial was a single-arm, phase II study that showed promising activity of the programmed death-1 (PD-1) inhibitor camrelizumab plus the vascular endothelial growth factor receptor-2 inhibitor apatinib in patients with...

Full description

Bibliographic Details
Main Authors: Xin Huang, Yang Shao, Dongqin Zhu, Jiani C Yin, Zhimin Liu, Chunyan Lan, Minjun He, Hongyu Peng, Chongjie Tong, Junli Zhang
Format: Article
Language:English
Published: BMJ Publishing Group 2021-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/5/e002223.full

Internet

https://jitc.bmj.com/content/9/5/e002223.full

Similar Items